Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
PD-1 blockade plus chemotherapy demonstrated superior efficacy than PD-1 blockade monotherapy or chemotherapy alone in patients with oncogenic-driven advanced NSCLC, particularly in KRAS, EGFR and BRAF subgroups. These findings suggest that PD-1 blockade plus chemotherapy may be considered as an optional treatment option for patients without available targeted therapies.
Authors
- Caicun Zhou (ORCID: https://orcid.org/0000-0002-2246-5541)
- Ying Ma (ORCID: https://orcid.org/0000-0001-7611-597X)
- Lei Cheng (ORCID: https://orcid.org/0000-0002-6529-288X)
- Fei Zhou (ORCID: https://orcid.org/0000-0003-1216-2181)
- Xuefei Li (ORCID: https://orcid.org/0000-0003-0188-5667)
- Chao Zhao (ORCID: https://orcid.org/0000-0003-1739-1151)
- Jian Chen (ORCID: https://orcid.org/0009-0004-5036-7721)
- Tao Jiang (ORCID: https://orcid.org/0000-0002-9205-8183)
- Peixin Chen (ORCID: https://orcid.org/0000-0002-4192-8396)
- Xiaoxia Chen (ORCID: https://orcid.org/0000-0002-2421-747X)
- Qianyi Wang (ORCID: https://orcid.org/0009-0002-4405-7888)
- Zhuoran Tang
- Haowei Wang (ORCID: https://orcid.org/0009-0004-1186-4303)
Institutions
- Tongji University (CN)
- Shanghai Pulmonary Hospital (CN)
- Shanghai East Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s00262-024-03937-6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Shanghai Rising-Star Program
- Shanghai Municipal Health and Family Planning Commission